Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2004.03.040
Annals of Surgical Oncology 11:304-309 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyers, M. O.
Right arrow Articles by Eisenberg, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyers, M. O.
Right arrow Articles by Eisenberg, B. L.
Related Collections
Right arrow Prognostic factors
Right arrow Surgery

ORIGINAL ARTICLES

Is Reporting of Recurrence Data Important in Pancreatic Cancer?

Michael O. Meyers, MD, Ingrid M. Meszoely, MD, John P. Hoffman, MD, James C. Watson, MD, Eric Ross, PhD and Burton L. Eisenberg, MD

From the Departments of Surgery (MOM, IMM, JPH, JCW, BLE) and Biostatistics (ER), Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Correspondence: Address correspondence and reprint requests to: John P. Hoffman, MD, Department of Surgery, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111; Fax: 215-728-2773; E-mail: jp_hoffman{at}fccc.edu

Background: Therapeutic approaches to patients with pancreatic cancer have undergone a paradigm shift in recent years. However, little is known about the outcome of patients with recurrent pancreatic cancer who undergo treatment. The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome.

Methods: A review of all patients undergoing surgical resection with curative intent revealed 70 patients with documented recurrence and complete medical records. Patients were grouped into three categories: group 1 included those who received treatment after recurrence (n = 45), group 2 included those who were not offered treatment (n = 9), and group 3 included those with poor performance status who received no treatment (n = 16).

Results: The median overall survival for the three groups was 26, 18, and 14.5 months for groups 1, 2, and 3, respectively (P < .00001). The median survival after recurrence was 10 months, 6 months, and 1 month, respectively, for the three groups (P < .0001).

Conclusions: This is the first series we are aware of that compares the outcomes of patients who received treatment after recurrence of pancreatic cancer with the outcomes of those who received no treatment. In this series, it seems that patients who were well enough to tolerate additional therapy had a longer survival than those who received supportive care only. This may be important in the analysis of adjuvant therapy trials of pancreatic cancer with survival as an end point.

Key Words: Pancreatic cancer • Recurrence • Chemotherapy • Survival treatment






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.